Simplesa Releases Degenerative Protocol Spectrum (DPS) for ALS Patients
Simplesa released its Degenerative Protocol Spectrum (DPS), a nutritional supplement regimen specifically formulated for people suffering with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease). The formulation is based on the Deanna Protocol, which has been shown to improve patient health and reduce the progression of symptoms. DPS includes 27 individual ingredients simplified into seven products.
Coral Springs, FL, February 11, 2014 --(PR.com)-- Simplesa LLC, a company that develops nutritional formulations for patients following complex regimens, released the Degenerative Protocol Spectrum (DPS). The Degenerative Protocol Spectrum is based on Dr. Vincent Tedone’s Deanna Protocol used by patients with Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s Disease). The Degenerative Protocol Spectrum is a 27-ingredient protocol that optimizes and re-formulates the Deanna Protocol so that it is easier for patients to follow, but also regains some of the efficacy that was purportedly lost in the latest revisions of the Deanna Protocol.
The current Deanna Protocol, as laid out by the 501(c)3 nonprofit WINNING THE FIGHT, INC, is a substantially modified version of Dr. Tedone’s original Deanna Protocol. Dr. Tedone, who is the medical liaison for WINNING THE FIGHT, INC, has suggested that the changes to the protocol were made to make it easier for patients to take and to reduce the cost.
Anecdotal accounts suggest, however, that some of the benefits may have been lost in the latest version. Steve Margolis, Co-Founder of Simplesa explains, “ALS patients who have been taking the Deanna Protocol for some time have noticed that the recent changes to the regimen compromise some of the benefits. They just don’t think it works as well and they don’t feel like they’re getting the full potential. They think the older Deanna Protocol was more helpful.” The Degenerative Protocol Spectrum was formulated to recapture the effectiveness of Dr. Tedone’s earlier Deanna Protocol while keeping costs down and streamlining dosing. The final formulation and dosages for the Degenerative Protocol Spectrum were developed based on the most recent research available in ALS.
“We wanted to offer a protocol for ALS patients who do not want to compromise,” Mr. Margolis continues. “They become used to experiencing the benefits of the Deanna Protocol and didn't want to cut corners when it came to potency or effectiveness. We expended considerable time and resources developing the DPS to meet this patient demand. They deserve quality and convenience without compromise.”
Patients will be able to purchase the Degenerative Protocol Spectrum from NutriVine Vitamins, LLC and other professional health care practitioners. NutriVine Vitamins began offering all of the supplements included in the original versions of the Deanna Protocol in early 2013. Mike Siers, Director of NutriVine Vitamins, LLC states, “we are excited that Simplesa has taken the lead in developing this new protocol. We've already updated our infrastructure to support sales and distribution of DPS. I think PALS (People with ALS) will appreciate how we've tried to make the process as easy as possible and that we only offer the highest quality nutritional supplements and vitamins.”
As part of the release of the Degenerative Protocol Spectrum, Simplesa has produced two whitepapers detailing the DPS, one for medical professionals and the other targeted at patients with ALS and their caregivers. These whitepapers provide a scientific rationale for each of the included ingredients and detail some of the potential synergisms among the ingredients. The whitepapers are available to the public at www.SimplesaNutrition.com.
About Simplesa LLC
Simplesa LLC was founded in 2013 to formulate nutritional supplements for patients who follow complex treatment protocols. The company's primary area of expertise is in neurodegenerative diseases. Simplesa develops products for patients with less common conditions often overlooked by larger companies seeking a larger volume of sales. Simplesa LLC focuses primarily on niche markets with underrepresented patient populations.
Contact:
Steve Margolis
Co-Founder and Vice President, Simplesa LLC
954-671-1640
Web Site: www.SimplesaNutrition.com
steve@simplesanutrition.com
The current Deanna Protocol, as laid out by the 501(c)3 nonprofit WINNING THE FIGHT, INC, is a substantially modified version of Dr. Tedone’s original Deanna Protocol. Dr. Tedone, who is the medical liaison for WINNING THE FIGHT, INC, has suggested that the changes to the protocol were made to make it easier for patients to take and to reduce the cost.
Anecdotal accounts suggest, however, that some of the benefits may have been lost in the latest version. Steve Margolis, Co-Founder of Simplesa explains, “ALS patients who have been taking the Deanna Protocol for some time have noticed that the recent changes to the regimen compromise some of the benefits. They just don’t think it works as well and they don’t feel like they’re getting the full potential. They think the older Deanna Protocol was more helpful.” The Degenerative Protocol Spectrum was formulated to recapture the effectiveness of Dr. Tedone’s earlier Deanna Protocol while keeping costs down and streamlining dosing. The final formulation and dosages for the Degenerative Protocol Spectrum were developed based on the most recent research available in ALS.
“We wanted to offer a protocol for ALS patients who do not want to compromise,” Mr. Margolis continues. “They become used to experiencing the benefits of the Deanna Protocol and didn't want to cut corners when it came to potency or effectiveness. We expended considerable time and resources developing the DPS to meet this patient demand. They deserve quality and convenience without compromise.”
Patients will be able to purchase the Degenerative Protocol Spectrum from NutriVine Vitamins, LLC and other professional health care practitioners. NutriVine Vitamins began offering all of the supplements included in the original versions of the Deanna Protocol in early 2013. Mike Siers, Director of NutriVine Vitamins, LLC states, “we are excited that Simplesa has taken the lead in developing this new protocol. We've already updated our infrastructure to support sales and distribution of DPS. I think PALS (People with ALS) will appreciate how we've tried to make the process as easy as possible and that we only offer the highest quality nutritional supplements and vitamins.”
As part of the release of the Degenerative Protocol Spectrum, Simplesa has produced two whitepapers detailing the DPS, one for medical professionals and the other targeted at patients with ALS and their caregivers. These whitepapers provide a scientific rationale for each of the included ingredients and detail some of the potential synergisms among the ingredients. The whitepapers are available to the public at www.SimplesaNutrition.com.
About Simplesa LLC
Simplesa LLC was founded in 2013 to formulate nutritional supplements for patients who follow complex treatment protocols. The company's primary area of expertise is in neurodegenerative diseases. Simplesa develops products for patients with less common conditions often overlooked by larger companies seeking a larger volume of sales. Simplesa LLC focuses primarily on niche markets with underrepresented patient populations.
Contact:
Steve Margolis
Co-Founder and Vice President, Simplesa LLC
954-671-1640
Web Site: www.SimplesaNutrition.com
steve@simplesanutrition.com
Contact
Simplesa LLC
Steve Margolis
954-671-1640
www.simplesanutrition.com
Steve Margolis
954-671-1640
www.simplesanutrition.com
Contact
Categories